G40.1 G40.2 G40.6
Conditions
Interventions
Group 1: The investigator will ask suitable patients to participate in this study. If the patient agrees to participate in the study, data on bone health are collected at baseline as well as 3, 6 and
Sponsors
Universitätsklinikum FreiburgEpilepsiezentrum
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male and female patients = 18 years of age; 2. Patients with partial-onset seizures with or without secondary generalization; 3. Treatment with eslicarbazepine-acetate; 4. Written informed consent to participate in the trial and ability to adhere to the protocol
Exclusion criteria
Exclusion criteria: 1. Comedication with phenobarbitone, primidone, carbamazepine, phenytoin, oxcarbazepine, valproate, corticosteroids; 2. Known pregnancy or planned pregnancy; 3. Immobilized patients; 4. Preexisting bone disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone density at baseline and at visit month 12 (measured by DXA hip and spine) will be compared intra-individually in the complete patient group. | — |
Secondary
| Measure | Time frame |
|---|---|
| Laboratory tests related to bone metabolism; additional parameters of treatment efficacy and tolerability are assessed systematically using seizure diaries and standardized questionnaires. | — |
Countries
Germany
Contacts
Public ContactAndreas Schulze-Bonhage
Universitätsklinikum FreiburgEpilepsiezentrum
Outcome results
None listed